Trial Profile

First-in-Human Phase I Study of TIGIT-Blocked NK510 Cells in Patients With PD-1 Refractory Advanced NSCLC

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 02 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; NK 510 (Primary) ; NK 510 (Primary) ; Sugemalimab (Primary) ; Tislelizumab (Primary)
Indications Malignant pleural effusion; Non-small cell lung cancer
Focus Adverse reactions
Sponsors Base Therapeutics

Most Recent Events

20 Mar 2026 Protocol amended to include patients with Malignant-pleural-effusion, patient number increased to 12.
20 Mar 2026 Planned number of patients changed from 9 to 12.
12 Sep 2025 Planned End Date changed from 1 Jul 2024 to 1 Jul 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com